QUE Oncology, Inc. (QUE) was formed in 2013 through a collaboration between Emory University’s Institute for Drug Development (EIDD), in Atlanta, Georgia, and the University of Queensland (UQ) research commercialization company, UniQuest, in Brisbane, Australia. QUE Oncology is developing novel therapies to address unmet medical needs in the treatment of cancer and its consequences. The Company has recently completed a Phase 1b clinical trial and is progressing a Phase 2 clinical study of its leading drug candidate Q-122, a non-hormonal therapy, for the treatment of hot flashes in women with breast cancer who are receiving anti-estrogen therapy (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01977-8/fulltext)
Hot flashes affect two thirds of postmenopausal women, and 10%–20% of all postmenopausal women find them nearly intolerable. Hot flashes are the most usual complaint of perimenopausal and postmenopausal women. Hot flashes are very common in breast cancer survivors after treatment as well as because of some adjuvant treatment, such as tamoxifen. They are significantly more frequent and more severe in breast cancer patients than in women without a diagnosis of breast cancer.